Linvoseltamab, a BCMA-directed CD3 T-cell engager for multiple myeloma: a patient-centric option via a response-adapted dosing regimen.
3/5 보강
TL;DR
Linvoseltamab is the fourth FDA approved bispecific antibody for the treatment of RRMM in patients who have received four or more lines of therapy, and cross-trial comparisons suggested that linvoseltamab has comparable to slightly better efficacy compared with other agents.
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
환자: progression through multiple lines of therapy
I · Intervention 중재 / 시술
four or more lines of therapy
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Linvoseltamab offers an optimized dosing regimen with a favorable CRS profile. Further real-world data are needed to understand linvoseltamab's role within the MM treatment paradigm.
OpenAlex 토픽 ·
Multiple Myeloma Research and Treatments
CAR-T cell therapy research
Monoclonal and Polyclonal Antibodies Research
Linvoseltamab is the fourth FDA approved bispecific antibody for the treatment of RRMM in patients who have received four or more lines of therapy, and cross-trial comparisons suggested that linvoselt
APA
J. Lowy, Michael Rogers, et al. (2026). Linvoseltamab, a BCMA-directed CD3 T-cell engager for multiple myeloma: a patient-centric option via a response-adapted dosing regimen.. Expert review of hematology, 19(4), 361-372. https://doi.org/10.1080/17474086.2026.2634283
MLA
J. Lowy, et al.. "Linvoseltamab, a BCMA-directed CD3 T-cell engager for multiple myeloma: a patient-centric option via a response-adapted dosing regimen.." Expert review of hematology, vol. 19, no. 4, 2026, pp. 361-372.
PMID
41708325 ↗
Abstract 한글 요약
[INTRODUCTION] Despite advances in the treatment of multiple myeloma (MM), there remains a significant need for new modalities, mechanisms of action (MOA), and combinations to achieve durable remissions. Bispecific T-cell engagers (BiTEs), particularly those targeting B-cell maturation antigen (BCMA), have demonstrated robust outcomes in patients with progression through multiple lines of therapy. Linvoseltamab, a novel BCMAxCD3 bispecific, was recently the FDA and EMA-approved based on the LINKER-MM1 trial for the treatment of patients with relapsed or refractory multiple myeloma (RRMM) who have progressed beyond four lines of therapy.
[AREAS COVERED] We will discuss the MOA, pharmacokinetics, efficacy, and toxicity of linvoseltamab compared with other approved BiTEs. We will highlight linvoseltamab's patient-centric dosing regimen and improved side effect profile, and we will review published indirect efficacy comparisons with other approved BCMA directed therapies.
[EXPERT OPINION] Linvoseltamab is the fourth FDA approved bispecific antibody for the treatment of RRMM in patients who have received four or more lines of therapy. Cross-trial comparisons ave suggested that linvoseltamab has comparable to slightly better efficacy compared with other agents. Linvoseltamab offers an optimized dosing regimen with a favorable CRS profile. Further real-world data are needed to understand linvoseltamab's role within the MM treatment paradigm.
[AREAS COVERED] We will discuss the MOA, pharmacokinetics, efficacy, and toxicity of linvoseltamab compared with other approved BiTEs. We will highlight linvoseltamab's patient-centric dosing regimen and improved side effect profile, and we will review published indirect efficacy comparisons with other approved BCMA directed therapies.
[EXPERT OPINION] Linvoseltamab is the fourth FDA approved bispecific antibody for the treatment of RRMM in patients who have received four or more lines of therapy. Cross-trial comparisons ave suggested that linvoseltamab has comparable to slightly better efficacy compared with other agents. Linvoseltamab offers an optimized dosing regimen with a favorable CRS profile. Further real-world data are needed to understand linvoseltamab's role within the MM treatment paradigm.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.